Anti-Human CEACAM5 (CD66e) (Labetuzumab) (C2540-1.0mg)

CEACAM5 is a member of the carcinoembryonic antigen-related cellular adhesion molecules (CEACAM) family1. In normal tissues, CEACAM5 functions as an adhesion molecule and has roles in differentiation, immune modulation, and anoikis inhibition. Additionally, CEACAM5 likely inhibits terminal differentiation and is also involved in activation of CD8+ suppressor T cells. Dysregulation of CEACAM5 has been implicated in tumor initiation, progression, invasion, and metastasis1,2 as well as in immune-related disease, particularly ulcerative colitis1. CEACAM5 is a clinical biomarker for colon cancer1 and is also a promising target of anti-cancer immunotherapy2. CEACAM5 is a mediator of CEACAM1-induced apoptosis, and preventing this interaction may prove beneficial to cancer treatment by blocking immune evasion by cancer cells. hMN-14 (Labetuzumab; IMMU-130) is a CEACAM5 antibody-drug conjugate composed of a humanized CEACAM5 monoclonal antibody conjugated via the hydrolysable linker CL2A to 7- ethyl-10-hydroxycamptothecin (SN-38), a potent topoisomerase I inhibitor3,4. The antitumor activity of labetuzumab has been tested for colorectal4,7 and prostate cancers2. This non-therapeutic biosimilar is not a drug conjugate and thus does not contain the drug SN- 38.